Innovative Therapy Shows Promise for Rare ALS Treatment

A groundbreaking experimental drug shows promising results in treating a rare, genetically driven form of ALS, highlighting hope for functional recovery and disease modification.
Recent advancements in ALS research have highlighted the potential of an experimental drug that may offer hope for patients with a rare, aggressive form of the disease linked to specific genetic mutations. Dr. Neil Shneider, a neurologist at Columbia University Irving Medical Center, reports remarkable improvements in some patients treated with this novel therapy, ulefnersen, which was developed through his research efforts.
ALS, or amyotrophic lateral sclerosis, is a neurodegenerative disease that affects nerve cells responsible for muscle control. While most cases are sporadic, a small percentage, about 1-2%, are caused by mutations in the FUS gene. These mutations lead to the accumulation of toxic FUS proteins in motor neurons, rapidly progressing and often beginning in adolescence or young adulthood.
In a case series published in The Lancet, 12 patients with FUS-related ALS received ulefnersen. Two patients experienced extraordinary recoveries: a young woman who regained the ability to walk and breathe without assistance after years of decline, and a man in his mid-30s who remained symptom-free for three years despite being at high risk of developing symptoms. Overall, patients showed a significant reduction—up to 83%—in neurofilament light, a biomarker of nerve damage.
These results suggest that early intervention with targeted therapy can not only slow the progression but potentially reverse some functional losses in ALS patients. The treatment was well tolerated, with no serious side effects reported. Following these promising findings, a global clinical trial of ulefnersen is underway, with hopes of gaining regulatory approval.
The development of ulefnersen originated from efforts to help a single patient and evolved into a broader clinical approach. It employs antisense oligonucleotides—short DNA sequences designed to silence harmful gene expressions—targeting the FUS gene. This innovative approach aligns with precision medicine principles, aiming to tailor treatment based on individual genetic profiles.
Since its initial use in 2019 through expanded access programs, at least 25 patients worldwide have received ulefnersen. Researchers remain optimistic about its potential to alter the disease course and improve quality of life for those with this devastating condition.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Impact of Abortion Bans on Maternal Mortality and Health Risks
New research forecasts increased maternal mortality and health risks following abortion bans in the US, emphasizing ongoing disparities and healthcare challenges.
Limited Use of Genetic Testing for Children with Autism and Intellectual Disabilities in Medicaid Despite Guidelines
Despite clinical guidelines, genetic testing for children with autism and intellectual disabilities remains underutilized in Medicaid, with disparities affecting minority groups. A recent study urges policy and practice reforms to improve access and diagnosis.
Combined Exposure to BPA and Retinoic Acid Can Impair Brain Development by Altering Gene Expression
Research reveals that combined exposure to bisphenol A (BPA) and retinoic acid (RA) can interfere with early brain and facial development by overstimulating gene expression, posing risks to fetal neurodevelopment.